Background: Severe steroid-insensitive asthma is a substantial clinical problem. Effective treatments are urgently required, however, their development is hampered by a lack of understanding of the mechanisms of disease pathogenesis. Steroid-insensitive asthma is associated with respiratory tract infections and noneosinophilic endotypes, including neutrophilic forms of disease. However, steroid-insensitive patients with eosinophil-enriched inflammation have also been described. The mechanisms that underpin infection-induced, severe steroid-insensitive asthma can be elucidated by using mouse models of disease. Objective: We sought to develop representative mouse models of severe, steroid-insensitive asthma and to use them to identify pathogenic mechanisms and investigate new treatment approaches. Methods: Novel mouse models of Chlamydia, Haemophilus influenzae, influenza, and respiratory syncytial virus respiratory tract infections and ovalbumin-induced, severe, steroid-insensitive allergic airway disease (SSIAAD) in BALB/c mice were developed and interrogated. Results: Infection induced increases in the levels of microRNA (miRNA)-21 (miR-21) expression in the lung during SSIAAD, whereas expression of the miR-21 target phosphatase and tensin homolog was reduced. This was associated with an increase in levels of phosphorylated Akt, an indicator of phosphoinositide 3-kinase (PI3K) activity, and decreased nuclear histone deacetylase (HDAC)2 levels. Treatment with an miR-21-specific antagomir (Ant-21) increased phosphatase and tensin homolog levels. Treatment with Ant-21, or the pan-PI3K inhibitor LY294002, reduced PI3K activity and restored HDAC2 levels. This led to suppression of airway hyperresponsiveness and restored steroid sensitivity to allergic airway disease. These observations were replicated with SSIAAD associated with 4 different pathogens. Conclusion: We identify a previously unrecognized role for an miR-21/PI3K/HDAC2 axis in SSIAAD. Our data highlight miR-21 as a novel therapeutic target for the treatment of this form of asthma. (J Allergy Clin Immunol 2017;139:519-32.)
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Corticosteroids are broad-acting anti-inflammatory agents and the mainstay treatments for asthma. 1 However, 5% to 10% of asthmatic patients do not respond to steroid treatment. These patients typically have more severe disease, account for 50% or more of asthma-associated health care costs, and urgently require effective therapies. 2, 3 Asthma is an inflammatory condition of the airways archetypally mediated by aberrant T H 2 lymphocyte responses 4 that drive eosinophilic airway inflammation, mucus hypersecretion, and airway hyperresponsiveness (AHR). 5 Recent clinical evidence shows that asthma is a heterogeneous condition. Indeed, increased T H 1 and/or T H 17 responses 6 and noneosinophilic, predominantly neutrophilic airway inflammation prevail in patients with moderate-to-severe asthma. 7 Severe asthma is often steroid insensitive and is associated with noneosinophilic endotypes of disease, particularly neutrophilic asthma. 8, 9 However, persistent eosinophilic airway inflammation in patients with steroid-insensitive asthma has been described, 10, 11 suggesting that severe, steroid-insensitive (SSI) asthma may also be associated with this type of inflammation.
The anti-inflammatory effects of corticosteroids are largely mediated through activation of the nuclear receptor subfamily 3, group C, member 1 (NR3C1; commonly termed the cytosolic glucocorticoid receptor [GR]) 12 and recruitment of histone deacetylase (HDAC)2, which deacetylates histones and suppresses gene transcription. 13 Reduced HDAC2 activity is associated with both SSI asthma and chronic obstructive pulmonary disease (COPD). [14] [15] [16] Steroid insensitivity and reduced HDAC2 activity are both linked to aberrant phosphoinositide 3-kinase (PI3K) activity. Pharmacologic and genetic interruption of PI3K function reinstated steroid sensitivity and HDAC2 activity in experimental COPD. 16, 17 Thus, exaggerated PI3K activity may promote steroid insensitivity by reducing HDAC2 responses.
Substantial clinical and experimental evidence links respiratory bacterial and viral infections with SSI asthma. Chlamydiaassociated asthma has increased airway neutrophils that predict the presence of the bacterium and is resistant to steroid treatment. [18] [19] [20] [21] Haemophilus influenzae is commonly isolated from the airways of patients with SSI asthma, and its presence correlates with more severe airflow obstruction, neutrophilic inflammation, and steroid insensitivity. [22] [23] [24] These infections induce neutrophilic T H 1 and/or T H 17 responses in experimental asthma models (allergic airway disease [AAD]), replicating the effects in patients. [25] [26] [27] [28] Respiratory tract infections with influenza and respiratory syncytial virus (RSV) induce asthma exacerbations that are steroid-insensitive. 29, 30 PI3K activity promotes T H 17 immune responses and facilitates the entry of these pathogens into host cells, and promotes their replication that further activates PI3K. [31] [32] [33] [34] [35] Several microRNAs (miRNAs) are implicated in asthma pathogenesis, and miRNA-21 (miR-21) is important in murine AAD.
36-39 miR-21-deficient mice exhibit reduced eosinophilic inflammation and IL-4 levels, with a concomitant increase in IFN-g levels, during ovalbumin (OVA)-induced AAD. 40 miR-21 can also downregulate the expression of phosphatase and tensin homolog (PTEN), which antagonizes PI3K activity. [41] [42] [43] We assessed the roles of miR-21 and PI3K in the pathogenesis of severe, steroid-insensitive allergic airway disease (SSIAAD). We first developed novel mouse models of Chlamydia, Haemophilus influenzae, influenza, and RSV infection-induced SSIAAD that recapitulate the hallmark features of SSI asthma. Then we interrogated them to show that infection-induced miR-21 promotes SSIAAD by reducing PTEN, amplifying PI3K-dependent activity, and suppressing HDAC2. These effects were attenuated and steroid sensitivity was restored by inhibiting miR-21 or PI3K. Thus, we define a novel miR-21/PI3K/HDAC2 axis in a previously unrecognized pathogenic role and identify miR-21 as a novel therapeutic target in patients with SSI asthma.
METHODS
The murine model of established AAD, dexamethasone treatment, respiratory tract infections in established AAD, miR-21 and PI3K inhibition, airway inflammation, AHR, quantification of mRNA and miR-21 expression, miR-21 in situ hybridization, immunoblot analyses, and statistics 25, 31, 39, [44] [45] [46] [47] [48] [49] [50] [51] [52] are described in the Methods section, and Figs E1-E5 and Table E1 in this article's Online Repository at www.jacionline.org.
RESULTS

Chlamydia respiratory tract infection induces SSIAAD
OVA-induced AAD was established in BALB/c mice, which were then infected with Chlamydia muridarum (Cmu; see Fig E1) . This is a natural mouse respiratory pathogen and the most appropriate Chlamydia strain for studying host-pathogen relationships in mice. 28, 47, [53] [54] [55] [56] [57] In the absence of infection, AAD (OVA/sucrose phosphate glutamate buffer [SPG] ) was characterized by predominantly eosinophilic airway inflammation and AHR compared with nonallergic (Sal/SPG) controls (Fig 1, A-G) . Resolved Chlamydia infection suppressed eosinophilic and increased neutrophilic airway inflammation in mice with AAD and had no effect on the magnitude of AHR (OVA/Cmu vs OVA/SPG ; Fig 1, F and G) . Resolved infection alone (Sal/Cmu) did not induce persistent airway inflammation or AHR compared with Sal/SPG (Fig 1,  A-G) , suggesting that Chlamydia-induced neutrophilic AAD results from a change in AAD phenotype rather than having additive effects on inflammation and AHR. Dexamethasone treatment (see Fig E1) inhibited airway inflammation and AHR in the setting of AAD (OVA/SPG/DEX vs OVA/SPG ; Fig 1, A-G (Fig 1, I) .
Chlamydia infection induces a persistent increase in miR-21 expression in mice with SSIAAD Because miR-21 is implicated in the pathogenesis of asthma, [36] [37] [38] [39] [40] we assessed its expression in Chlamydia-induced SSIAAD (OVA/Cmu). Lung miR-21 expression was increased on day 35 compared with Sal/SPG controls (Fig 1, J) . However, all allergic and/or infected groups had increased expression, with a trend toward higher levels in infected groups. Importantly, all infected groups, regardless of allergic status, exhibited increased miR-21 expression on day 35 compared with sham-infected nonallergic (Sal/SPG) controls. Thus, Chlamydia infection substantially and chronically increases miR-21 expression, even in the absence of allergic responses. Interestingly, the increased expression of miR-21 in Chlamydia-infected nonallergic (Sal/Cmu) mice is associated with increased expression of several T H 1-and T H 17-associated factors (ie, Stat1, Ifng, Tnf, Il17, and Il6) identified in Fig 1, H , compared with that seen in sham-infected (Sal/SPG) control mice (see Fig E2, A) . This suggests that miR-21 is an infection-induced factor that may potently affect the lung environment prior to allergen challenge in Chlamydia-infected groups and play a role in the induction of SSIAAD.
We also conducted miR-21 quantitative PCR analyses on lung tissue from C57BL/6 mice that were subjected to OVA-induced AAD or infected with C muridarum. We show that miR-21 expression is increased by AAD and infection in a similar manner to that observed in BALB/c mice (see Fig E2, B and C). These data show that induction of miR-21 by AAD and infection is not mouse strain specific.
Then we showed that miR-21 expression was widespread, occurring in airway epithelial, endothelial, and infiltrating immune cells (see Fig E3) . 9, 58 Dexamethasone had no effect on miR-21 expression in allergic groups (Ova/SPG/DEX and OVA/Cmu/DEX), indicating that its expression is steroid insensitive, irrespective of the presence of infection.
Chlamydia infection primes steroid-insensitive responses in mice with AAD that are associated with increased miR-21 expression
To examine this potential, we next examined the Chlamydia infection-induced lung environment on day 32 immediately before dexamethasone treatment and OVA rechallenge. Chlamydia-infected allergic (OVA/Cmu) mice exhibited increased miR-21 expression (Fig 2, A) , with concurrent decreases in the expression of Pten, Nr3c1, and Hdac2 (Fig 2, B-D) compared with that seen in the OVA/SPG groups. These factors are involved in PI3K-dependent and steroid-mediated responses. To determine whether these Chlamydia-induced effects were associated with increased PI3K function, we also assessed the levels of phosphorylated AKT (pAKT), a surrogate marker of PI3K-dependent activity. OVA/Cmu mice had increased pAKT and reduced HDAC2 protein levels in their lung nuclear fractions (Fig 2, E and F). In contrast, these mice had decreased pAKT (see Fig E4) levels in lung cytoplasmic fractions, suggesting that infection resulted in increased nuclear translocation of pAKT. Collectively, these data show that Chlamydia-induced miR-21 expression at the time of steroid treatment in mice with SSIAAD is associated with attenuated Nr3c1 expression, increased PI3K responses, and reduced HDAC2 levels. SSIAAD groups that were sham treated (OVA/Cmu/Scram) had increased pAKT and reduced HDAC2 levels in lung nuclear fractions compared with levels in OVA/SPG/Scram control mice (Fig 1, A) , eosinophil (Fig 1, B) , neutrophil (Fig 1, C) , macrophage (Fig 1, D) , and lymphocyte (Fig 1, E) numbers in bronchoalveolar lavage fluid (BALF) on day 35 (see Fig E1) in Cmu-and sham (SPG)-infected groups with OVA-induced AAD with or without dexamethasone (DEX) treatment compared with nonallergic control mice (Sal; > _2 experiments, n 5 4-10 per group). F and G, AHR in terms of airway resistance (Rn ; Fig 1, F) to increasing doses of methacholine (MCh) and 10 mg/mL MCh (Fig 1, G; statistics at maximal dose from AHR curves [Fig 1, F] ). H, Lung mRNA expression of T H 1-and T H 17-associated factors. I, Common features of SSI asthma and SSIAAD. J, Expression of miR-21 in lung tissue (> _2 experiments, n 5 4-6 per group). Data are means 6 SEMs. *P < .05, **P < .01, ***P < .001, and ****P < .0001. (Fig 3, D and E Ant-21 also completely inhibited AHR to baseline levels observed in OVA/SPG/Scram/DEX control mice, irrespective of the presence of steroids. These data show that infection-induced miR-21 expression promotes steroid-insensitive airway inflammation and inflammation-and dexamethasone-independent AHR in the setting of SSIAAD.
We then assessed the role and potential for therapeutic targeting of miR-21 in mice with steroid-sensitive AAD (OVA/SPG/Ant-21, see Fig E5) . Ant-21 treatment induced a close to statistically significant decrease in inflammation (P 5 .067 difference for total leukocytes, significant reduction in eosinophils) and inhibited AHR to baseline levels observed in DEX-treated (OVA/SPG/Scram/ DEX) control animals.
These data demonstrate that Chlamydia-induced miR-21 expression plays important roles in increasing pAKT and reducing HDAC2 levels, which regulate the steroid sensitivity of airway inflammation and induction of steroid-insensitive AHR.
PI3K activity increases pAKT and reduces HDAC2 levels to induce SSIAAD
We next examined the role of PI3K activity in Chlamydiainduced SSIAAD. Administration of the pan-PI3K inhibitor LY294002 increased Hdac2 mRNA expression in mice with SSIAAD (OVA/Cmu/LY29 vs OVA/Cmu/dimethyl sulfoxide [DMSO]; Fig 4, A) . LY294002 also suppressed pAKT and restored HDAC2 protein levels in lung nuclear fractions in mice with SSIAAD with or without DEX (OVA/Cmu/LY29 with or without DEX) compared with sham-treated control animals (OVA/Cmu/DMSO with or without DEX; Fig 4, B and C) . LY294002 treatment, in the presence of DEX, suppressed inflammation in mice with SSIAAD (Fig 4, D-H) . However, this suppression did not occur in the absence of DEX, where inflammation was increased (OVA/Cmu/LY29 vs OVA/Cmu/ DMSO). LY294002 alone, like Ant-21, suppressed AHR in mice with SSIAAD, with greater effects in combination with DEX, where responsiveness was inhibited to baseline levels observed in DEX-treated sham-infected AAD (OVA/SPG/ DMSO/DEX).
Thus, Chlamydia-induced PI3K activity also plays important roles in increasing pAKT and reducing HDAC2 levels in the regulation of steroid sensitivity of airway inflammation and the induction of steroid-insensitive AHR in mice with SSIAAD. Taken together, our data demonstrate that Chlamydia respiratory (Fig 2, A) , Pten (Fig 2, B) , Nr3c1 (Fig 2, C) , and Hdac2 (Fig 2, D) was assessed on day 32 by using quantitative PCR in Cmu-and sham (SPG)-infected allergic mice (see Fig E1; 1 experiment, n 5 8 per group). E and F, Nuclear protein levels of pAKT, AKT, and pAKT/AKT ratio (Fig 2, E) and HDAC2 (Fig 2, F) determined by using immunoblot (top panels) and densitometry (bottom panels; > _2 experiments, n 5 4 per group). Data are means 6 SEMs. **P < .01, ***P < .001, and ****P < .0001.
tract infection drives an miR-21-dependent, PI3K-mediated axis that induces SSIAAD.
Inhibition of miR-21 suppresses hallmark features of Haemophilus-induced SSIAAD
To assess the broader applicability of our findings to SSI asthma induced by other bacterial infections, we developed a novel model of nontypeable Haemophilus influenzae (Hinf)-induced SSIAAD and examined the role and potential of therapeutic targeting of miR-21 (see Fig E1) . Like with Chlamydia, H influenzae infection induced the key features of neutrophilic SSIAAD, with increased neutrophilic airway inflammation and AHR that were steroid insensitive (Fig 5) . Collectively, our data demonstrate that miR-21 and an miR-21/ PI3K/HDAC2 axis play important roles in the induction of steroid-insensitive airway inflammation and AHR in bacterial (Chlamydia and Haemophilus) and viral (influenza and RSV) infection-induced SSIAAD.
DISCUSSION
We developed novel experimental models of SSI asthma that are driven by bacterial (Chlamydia and Haemophilus) and viral (influenza and RSV) respiratory tract infections. These models recapitulate the hallmark features of this form of human asthma, including exaggerated T H 1/T H 17 responses and steroid-insensitive airway inflammation and AHR. By interrogating our models and using an antagomir that specifically depletes miR-21 and the pan-PI3K inhibitor LY294002, we demonstrate that infection-induced miR-21 expression promotes PI3K-mediated phosphorylation and nuclear translocation of pAKT that suppresses HDAC2 levels and leads to steroid insensitivity (Fig 8) .
We previously showed that an ongoing Chlamydia respiratory tract infection during systemic sensitization to OVA leads to exaggerated T H 1 (Ifng)/T H 17 (Il17) responses and neutrophilic inflammation in AAD. 28 In patients with SSI asthma, we propose that it is infection in the setting of established asthma that drives the development of this form of disease. Here, we advance our previous studies 59 by developing a model that more accurately reflects the human scenario. We established AAD in mice and then induced a Chlamydia respiratory tract infection. AAD wanes over 20 days (unpublished observations), and therefore, to test the effect of a resolved infection on disease, we recapitulated the AAD phenotype with a second set of OVA challenges. This is representative of asthmatic patients exposed to respiratory tract infection and allergens and is reflective of what occurs in the community. We show that Chlamydia infection-induced AAD is characterized by exaggerated expression of a range of T H 1-associated (Tlr2, Stat1, Ifng, Cxcl9 and Cxcl10, and Tnf) and T H 17-associated (Il17, Il6, Tgfb, and Il1b) factors in the lung that are also increased in patients with severe neutrophilic asthma (Fig 1, I) . 6 Importantly, inflammation and AHR are steroid insensitive in this model, indicating that infection drives pathogenic processes that are not suppressed by anti-inflammatory steroid treatment. These data extend our (Fig 3, B) and Hdac2 (Fig 3, C) on day 35 in allergic groups not treated with dexamethasone (> _2 experiments, n 5 4-5 per group). D and E, Nuclear protein levels of pAKT, AKT, and pAKT/AKT ratio (Fig 3, D) and HDAC2 (Fig 3, E) on day 35 determined by using immunoblot (top panels) and densitometry (bottom panels; > _2 experiments, n 5 5 per group). F-J, Total leukocyte (Fig 3, F), eosinophil (Fig 3, G) , neutrophil (Fig 3, H) , macrophage (Fig 3, I) , and lymphocyte (Fig 3, J) numbers in bronchoalveolar lavage fluid (BALF; > _2 experiments, n 5 4-6 per group). K and L, AHR in terms of airway resistance (Rn; Fig 3, K) to increasing doses of methacholine (MCh) and 10 mg/mL MCh (Fig 3, L; statistics at maximal dose from AHR curves [ Fig 3, K] ; > _3 experiments, n 5 5-10 per group). Data are means 6 SEMs. *P < .05, **P < .01, ***P < .001, and ****P < .0001. (Fig 4, B) and HDAC2 (Fig 4, C) determined by using immunoblot (top panels) and densitometry (bottom panels; > _2 experiments, n 5 5 per group). D-H, Total leukocyte (Fig 4, D) , eosinophil (Fig 4, E) , neutrophil (Fig 4, F) , macrophage (Fig 4, G) , and lymphocyte (Fig 4, H) numbers in bronchoalveolar lavage fluid (BALF; > _2 experiments, n 5 4-8 per group). I and J, AHR in terms of airway resistance (Rn ; Fig 4,  I ) to increasing doses of methacholine (MCh) and 10 mg/mL MCh (Fig 4, J; statistics at maximal dose from AHR curves [ Fig 4, I] ; > _2 experiments, n 5 5-8 per group). Data are means 6 SEMs. *P < .05, **P < .01, ***P < .001, and ****P < .0001.
understanding of clinical studies that associate respiratory tract infections with noneosinophilic forms of asthma that are steroid insensitive. Indeed, substantial clinical evidence links Chlamydia respiratory tract infection in asthmatic patients with increased neutrophil numbers in the lungs during exacerbations and steroid insensitivity. [18] [19] [20] [21] Several different mechanisms have been implicated in the pathogenesis of SSI asthma, including altered immune responses, increased activity of transcription factors, and defective GR function.
3,60-62 However, notably, many patients with SSI asthma have normal nuclear translocation of GR and no deficit in GR:glucocorticoid response element binding affinity. 63 This indicates that steroid insensitivity in asthmatic patients can be driven by mechanisms outside of the canonical steroid response pathway. Thus, targeting specific factors that control multifunctional pathways may be the most effective therapeutic approach.
miRNAs can have potent effects on immunity, and increasing evidence shows that they have pathogenic roles in asthma. 37, 38, 64 miR-21 is highly induced in inflamed lungs and can promote eosinophilic inflammation and T H 2 responses while suppressing T H 1 immunity through the disruption of IL-12p35. 36, 40, 65 Consequently, miR-21 studies in asthma have focused on its role in immune polarization during allergic sensitization. 66 In this study, we demonstrate a previously unrecognized role for miR-21 in the setting of steroid insensitivity. miR-21 expression was increased in both mice with steroid-sensitive AAD and those with SSIAAD. However, sham-infected allergic mice only exhibited increased miR-21 expression after the recapitulation of AAD. This suggests that its upregulation in mice with steroid-sensitive AAD is a transient phenomenon acutely induced by the allergic inflammatory response. In contrast, infected allergic mice had persistently increased miR-21 expression on day 32 immediately before steroid treatment and OVA rechallenge and when Chlamydia-induced inflammation has subsided to baseline levels. Significantly, this effect was accompanied by concomitant reductions in mRNA expression of Pten, Nr3c1, and Hdac2. miR-21 has been shown to directly inhibit PTEN in both human and murine cells, which was shown by using PTEN reporter luciferase activity assays and inhibitors (human and mouse) and mimics (mouse) of miR-21. [41] [42] [43] Furthermore, under normal conditions, PTEN antagonizes PI3K activity by catalyzing the dephosphorylation of phosphatidylinositol 3,4,5-bisphosphate (Fig 5, A) , eosinophil (Fig 5, B) , neutrophil (Fig 5, C) , macrophage (Fig 5, D) , and lymphocyte (Fig 5, E) numbers in bronchoalveolar lavage fluid (BALF) on day 35 (see Fig E1) in Hinfand sham (PBS)-infected groups with OVA-induced AAD with or without DEX with or without miR-21-specific (Ant-21) or scrambled (Scram) antagomir (1 experiment, n 5 5-6 per group). F and G, AHR in terms of airway resistance (Rn; Fig 5, F) to increasing doses of methacholine (MCh) and 10 mg/mL MCh (Fig 5, G; statistics at maximal dose from AHR curves [ Fig 5, F] ; 1 experiment, n 5 5-6 per group). Data are means 6 SEMs. *P < .05, **P < .01, ***P < .001, and ****P < .0001.
into phosphatidylinositol 4,5-bisphosphate, which inhibits the recruitment and activation (by phosphorylation) of Akt. [67] [68] [69] Thus, we hypothesized that infection-induced miR-21 expression drives steroid insensitivity in AAD by suppressing PTEN, thereby potentiating PI3K activity (Fig 8) .
Several studies link PI3K activity with inflammation and AHR in AAD, and one showed that rhinovirus infection induced PI3K-dependent neutrophilic airway inflammation. 70 Here, we show that Chlamydia infection increased levels of nuclear pAKT, a well-established indicator of PI3K activity. 70 This effect was associated with decreased levels of nuclear HDAC2. Our findings are consistent with studies showing that PI3K-mediated reduction in HDAC2 expression and activity promotes steroid insensitivity. 2, 16, 17 Nonselective inhibition of PI3K activity with LY294002 restored HDAC2 activity and steroid sensitivity in the setting of experimental COPD. Furthermore, smoke-exposed PI3Kd dead knock-in transgenic mice have reduced tyrosine nitration of HDAC2 with no deficit in steroid sensitivity. 16, 17 Thus, infection-induced miR-21 expression may disrupt PTEN activity and amplify PI3K activity, which mediates the phosphorylation and nuclear translocation of AKT, resulting in reduced HDAC2 levels and steroid insensitivity. To our knowledge, our study is the first to identify the axis encompassing the miR-21-dependent, PI3K-mediated suppression of HDAC2 in the pathogenesis of steroid insensitivity, and miR-21 as a therapeutic target with activity that can be attenuated in vivo with specific inhibitors to reverse its effects.
We used 2 approaches to investigate the role and potential for therapeutic targeting of the miR-21-dependent, PI3K-mediated axis in SSIAAD. First, we inhibited miR-21 in vivo with miR-21-specific antagomir treatment. This approach has been shown to specifically and potently reduce the levels of targeted miRNAs. 37, 39 Treatment inhibited Chlamydia-induced miR-21 expression, restored Pten, reduced nuclear pAKT, and increased Hdac2/HDAC2 mRNA expression and protein levels in SSIAAD. Ant-21 suppressed steroid-insensitive airway inflammation when coadministered with steroids, demonstrating that targeted inhibition of miR-21 restored steroid sensitivity. Interestingly, AHR was attenuated by antagomir treatment alone in both steroid-insensitive and steroid-sensitive AAD, suggesting that miR-21 is an important mediator of the AHR in AAD. However, Chlamydia-infected nonallergic (Sal/Cmu) mice have increased miR-21 expression in the lungs but do not have AHR. This suggests that increased miR-21 expression does not (Fig 6, A) , eosinophil (Fig 6, B) , neutrophil (Fig 6, C) , macrophage (Fig 6, D) , and lymphocyte (Fig 6,  E) numbers in bronchoalveolar lavage fluid (BALF) on day 35 (see Fig E1) in Flu-and sham (Media)-infected groups with OVA-induced AAD with or without DEX with or without miR-21-specific (Ant-21) or scrambled (Scram) antagomir (1 experiment, n 5 5-8 per group). F and G, AHR in terms of airway resistance (Rn; Fig 6,  F) to increasing doses of methacholine (MCh) and 10 mg/mL MCh (Fig 6, G; statistics at maximal dose from AHR curves [ Fig 6, F] ; 1 experiment, n 5 7-8 per group). Data are means 6 SEMs. *P < .05, **P < .01, ***P < .001, and ****P < .0001.
induce AHR in the absence of AAD. Elucidating the miR-21-dependent mechanism of action that leads to AHR in AAD warrants further investigation and will be the focus of future studies. In contrast, antagomir treatment alone had no effect on inflammation in the setting of SSIAAD. Together, our findings suggest that steroid-insensitive airway inflammation and AHR have different etiologies but require the overexpression of miR-21 to maintain steroid insensitivity.
Our findings are consistent with several studies that show that treatment with inhaled steroids does not cause equivalent reductions in airway inflammation and AHR. [71] [72] [73] It is now well established that there is a disconnect between inflammation and AHR in asthmatic patients and that they are regulated by different processes. Indeed, in a study by Crimi et al, 72 no correlation was shown between the number of inflammatory cells present in sputum, BAL, or bronchial biopsy specimens and the level of AHR in patients with chronic asthma. 72 This study, as well as others, postulate that other noncanonical factors, such as airway remodeling and autonomic dysfunction that leads to persistently constricted airways, may drive the interindividual variation in AHR in asthmatic patients. 72, 74, 75 Our studies show that inhibiting miR-21 alone does not affect inflammation but suppresses AHR. However, the combination of miR-21 inhibition and dexamethasone treatment suppresses both of these features. This suggests that these 2 interventions are targeting the disconnected processes that drive inflammation and AHR in SSIAAD. Characterization of the pathways that underpin miR-21-induced AHR independently of inflammation is not within the scope of the current study but warrants future investigation. (Fig 7, A) , eosinophil (Fig 7, B) , neutrophil (Fig 7, C) , macrophage (Fig 7, D) , and lymphocyte (Fig 7, E) numbers in bronchoalveolar lavage fluid (BALF) on day 35 (see Fig E1) in RSV-and sham (UV-inactivated RSV [UV-RSV])-infected groups with OVA-induced AAD with or without DEX with or without miR-21-specific (Ant-21) or scrambled (Scram) antagomir (1 experiment, n 5 3-6 per group). F and G, AHR in terms of airway resistance (Rn; Fig 7, F) to increasing doses of methacholine (MCh) and 10 mg/mL MCh (Fig 7, G; statistics at maximal dose from AHR curves [ Fig 7, F] ; 1 experiment, n 5 5-6 per group). Data are means 6 SEMs. *P < .05, **P < .01, and ****P < .0001. To substantiate the existence of a pathogenic miR-21/PI3K axis, we then blocked PI3K activity in vivo with the pan-PI3K inhibitor LY294002 17, 70 and assessed the effect on SSIAAD. Inhibition reduced nuclear pAKT back to sham-infected levels similar to Ant-21 treatment. Steroid treatment alone had no effect on nuclear pAKT levels, indicating that PI3K activity is steroid insensitive. LY294002 also restored lung Hdac2/HDAC2 mRNA expression and nuclear protein levels and restored steroid sensitivity in a similar manner to Ant-21. The comparable effects of Ant-21 and LY294002 treatments suggest that infection initiates and maintains the activation of a pathogenic signaling axis comprised of both miR-21 and PI3K, which suppresses HDAC2 and leads to the induction of SSIAAD. Although miR-21 has many potential targets in the lung other than PTEN that could contribute to the induction of AHR in AAD in a non-PI3K-dependent manner, we show that both Ant-21 and LY294002 treatments suppress AHR in the absence of dexamethasone, which suggests that miR-21 may drive AHR in AAD through a PI3K-mediated pathway.
Although the current study demonstrates a novel pathogenic miR-21-dependent, PI3K-mediated pathway in the pathogenesis of SSIAAD, it does not identify specific cell types that express miR-21 that are important for the regulation of the miR-21/PTEN/ PI3K/HDAC2 pathway and thus glucocorticoid insensitivity. Our in situ hybridization analyses show that miR-21 is expressed in several cell types within the lung during SSIAAD (see Fig E3) . Thus, it is likely that multiple cell types are mediating these effects. Elucidating the relative contributions of individual cell types involved would further our understanding of how this pathway generates the cardinal features of SSIAAD. However, this is a major undertaking that will form the basis for future studies. In addition to the miR-21-dependent responses that are described in the current study, miR-21 and/or PTEN/PI3K responses have also been implicated in other disease processes in the lung, including profibrotic responses in patients with idiopathic pulmonary fibrosis, enhanced accumulation of myofibroblasts, and allergen-induced bronchial inflammation and AHR. [76] [77] [78] Thus, especially because miR-21 is expressed in multiple structural cells of the lung, it is likely that the miR-21/ PI3K/HDAC2 axis is involved in these processes and requires further study.
H influenzae respiratory tract infection is commonly associated with neutrophilic asthma that is steroid insensitive. 24 To assess the widespread applicability for targeting miR-21 in SSI asthma, we examined the effects of its inhibition in the setting of Haemophilus-induced SSIAAD. We previously showed that H influenzae infection induces T H 17-dominant immunity that drives neutrophilic, rather than eosinophilic, inflammatory responses in AAD 27 and that inflammation and AHR in this model are steroid insensitive. 26 Thus, we hypothesized that Haemophilus, like Chlamydia, induces SSIAAD through an miR-21-dependent mechanism. We first developed a novel and refined model of Haemophilus-induced SSIAAD in which infection is induced in established AAD. We showed that Ant-21 treatment also restored steroid sensitivity to inflammation and AHR in this model. Again, treatment suppressed AHR in the absence of steroids.
Because influenza virus and RSV respiratory tract infections have also been linked to SSI asthma, 29, 30 we developed novel models of influenza-and RSV-induced SSIAAD and assessed the wider applicability for targeting miR-21. Unlike bacteria-induced SSIAAD, both influenza-and RSV-induced AAD were characterized by steroid-insensitive eosinophilic airway inflammation and AHR. Some studies have shown that steroid-insensitive asthma can also be associated with persistent eosinophilic inflammation despite moderate-to high-dose steroid treatment. 10, 11 Furthermore, these viral infections enhance eosinophilic airway inflammation and T H 2 immune responses in other murine models of allergic asthma. 79, 80 Ant-21 treatment in the presence of steroids suppressed viral infection-induced, steroid-insensitive eosinophilic inflammation. These data suggest that respiratory tract bacterial and viral infection-induced miR-21 primes for steroid-insensitive responses but has minimal influence over the chemoattraction of specific immune cell types. Similar to bacteria-induced SSIAAD, Ant-21 treatment alone suppressed AHR in influenza-and RSV-induced SSIAAD. These data indicate that infection-induced miR-21 may also regulate inflammation-and steroid-independent pathways to induce steroid-insensitive AHR in AAD.
We also showed that Ant-21 treatment suppressed the key features of T H 2-mediated, steroid-sensitive AAD (ie, eosinophilic inflammation and AHR).
In summary, for the first time, our study demonstrates that miR-21 promotes steroid-insensitive inflammation and AHR in respiratory tract infection-induced SSIAAD. We define the functional relevance of infection-induced activation and maintenance of a novel miR-21/PI3K/HDAC2 axis in the setting of steroid insensitivity. Our study indicates that the inhibition of miR-21 may have broad therapeutic relevance to respiratory tract infection-induced SSI asthma and also steroid-sensitive, eosinophilic asthma. This is more attractive than targeting PI3K pathways because inhibition of miR-21 is upstream and more specific and can broadly affect both steroid-insensitive and steroid-independent networks, such as those that drive AHR that is independent of inflammation in the asthmatic lung.
Clinical implications: Respiratory tract infections drive SSIAAD through an miR-21/PI3K/HDAC2 axis. Targeting miR-21 or PI3K suppresses disease and restores steroid sensitivity, indicating the therapeutic potential of miR-21/PI3K-targeted therapies in combination with steroids in patients with SSI asthma.
